American Journal of BioMedicine Volume 10, Issue 1, pages 25-34
Geraldine M. Zingoni 1, Pablo D.Castillo 1, Cynthia B. Aliperti 1, David J. Horst 2
Avascular necrosis (AVN) of the femoral head (FH) is a debilitating and painful disease with multiple etiologic risk factors head shows an increasing tendency and most commonly affects younger or middle-aged adults. Fifty patients (55 hips) with stage I, II or III avascular necrosis of femoral head were treated by autologous Bone marrow-derived mesenchymal stem cells injection. The patients were followed up clinically and radiologically for a minimum of 2 years at baseline, three, six, 12, and 24 months. The functional outcome was assessed in terms of Harris hip score, and disease progression was assessed radiologically by comparing the preoperative and follow-up MRI at the end of 2 years. On 2-year follow-up, there was considerable improvement in the hip function as measured by the Harris hip score (p = 0.041). On MRI, there was a decrease in the size of the lesion in group A (p = 0.03). Our findings showed that autologous Bone marrow-derived mesenchymal stem cells in avascular necrosis of femoral head is a safe and effective procedure and has better outcome.
Keywords: Avascular necrosis; Stem cell therapy; Bone marrow-derived mesenchymal stem cells
Copyright © 2022 by American Journal of BioMedicine, Inc.
- Feng Y, Yang SH, Xiao BJ, Xu WH, Ye SN, Xia T. Decreased in the number and function of circulation endothelial progenitor cells in patients with avascular necrosis of the femoral head. Bone. 2010; 46:32-40.
- Hartley WT, McAuley JP, Culpepper WJ, Engh CA, Jr, Engh CA, Sr. Osteonecrosis of the femoral head treated with cementless total hip arthroplasty. J Bone Joint Surg Am. 2000; 82:1408-1413.
- Li ZH, Hu H, Zhang XY, Liu G.D, Ran B, Zhang PG. MiR-291a-3p regulates the BMSCs differentiation via targeting DKK1 in dexamethasone-induced osteoporosis. Kaohsiung J Med Sci. 2020; 36:35-42.
- Kuang MJ, Huang Y, Zhao XG, Zhang R, Ma JX, Wang DC. Exosomes derived from Wharton's jelly of human umbilical cord mesenchymal stem cells reduce osteocyte apoptosis in glucocorticoid induced osteonecrosis of the femoral head in rats via the miR-21-PTEN-AKT signalling pathway. Int J Biol Sci. 2019; 15:1861-1871.
- Peng W, Dong W, Zhang F, Wang J, Zhang J, Wu J. Effects of transplantation of FGF-2-transfected MSCs and XACB on TNF-α expression with avascular necrosis of the femoral head in rabbits. Biosci Rep. 2019; 39:1-10.
- Gangji V, Hauzeur JP, Matos C, De Maertelaer V, Toungouz M, Lambermont M. Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow cells. A pilot studies. J Bone Joint Surg Am. 2004; 86:1153-1160.
- Hauzeur JP, De Maertelaer V, Baudoux E, Malaise M, Beguin Y, Gangji V. Inefficacy of autologous bone marrow concentrate in stage three osteonecrosis: a randomized controlled double-blind trial. Int Orthop. 2017; 7:1429-1435.
- Houdek MT, Wyles CC, Collins MS, Howe BM, Terzic A, Behfar A. Stem cells combined with platelet-rich plasma effectively treat corticosteroid-induced osteonecrosis of the hip: a prospective study. Clin Orthop Relat Res. 2018; 476:388-397.
- Gangji V, Hauzeur JP. Treating osteonecrosis with autologous bone marrow cells. Skeletal Radiol. 2010; 39:209-211.
- Hernigou P, Beaujean F. Treatment of osteonecrosis with autologous bone marrow grafting. Clin Orthop Relat Res. 2002; 405:14-23.
- Houdek MT, Wyles CC, Packard BD, Terzic A, Behfar A, Sierra RJ. Decreased osteogenic activity of mesenchymal stem cells in patients with corticosteroid-induced osteonecrosis of the femoral head. J Arthroplasty. 2016; 31:893-898.
- Bjorkman A, Svensson PJ, Hillarp A et al. Factor V Leiden and prothrombin gene mutation. Clinical Orth Relat Res 2004; 425:168-172.
- Kanthan SR, Kavitha G, Addi S, Choon DS, Kamarul T. Platelet-rich plasma (PRP) enhances bone healing in non-united critical-sized defects: a preliminary study involving rabbit models. Injury. 2011; 42:782-789.
- Mont MA, Zywiel MG, Marker DR, McGrath MS, Delanois RE. The natural history of untreated asymptomatic osteonecrosis of the femoral head: a systematic literature review. J Bone Joint Surg Am. 2010; 92:2165-2170.
- Hernigou P, Trousselier M, Roubineau F et al. Stem cell therapy for the treatment of hip osteonecrosis: A 30-year review of progress. Clin Orthop Surg 2016; 8:1-8.10.
- Hernigou P, Beaujean F. Treatment of osteonecrosis with autologous bone marrow grafting. Clin Orthop. 2002; 405:14-23.
- Rastogi S, Sankineani SR, Nag HL, Mohanty S, Shivanand G, Marimuthu K, Kumar R, Rijal L. Intralesional autologous mesenchymal stem cells in management of osteonecrosis of femur: a preliminary study. Musculoskelet Surg. 2013; 97:223-228.
- Tripathy SK, Goyal T, Sen RK. Management of femoral head osteonecrosis: Current concepts. Indian J Orthop. 2015; 49(1): 28-45.
- Ming C, Min D, Yin Z. Isolation and culture of human bone marrow mesenchymal stem cells and induction of its differentiating into osteo- blasts in vitro. Orthop J of China. 2012; (01): 72-4.
- Zalavras C, Lieberman J. Osteonecrosis of the femoral head: evaluation and treatment. J Am Acad Orthop Surg. 2014; 22:455-64.
- Glueck CJ, Freiberg RA, Wang P. Heritable thrombophilia-hypofibrinolysis and osteonecrosis of the femoral head. Clinical Orth Relat Res. 2008; 466:1034-1040.
- Makihara T, Yoshioka T, Sugaya H et al. Autologous concentrated bone marrow grafting for the treatment of osteonecrosis of the humeral head: A report of five shoulders in four cases. Case Rep Orthop. 2017; 2017:4898057.
- Daltro GC, Fortuna V, de Souza ES et al. Efficacy of autologous stem cell-based therapy for osteonecrosis of the femoral head in sickle cell disease: A five-year follow-up study. Stem Cell Res Ther. 2015; 6:18.
- Hernigou P, Homma Y, Flouzat-Lachaniette C, et al. Cancer Risk Is Not Increased in Patients Treated for Orthopaedic Diseases with Autologous Bone Marrow Cell Concentrate[J]. J Bone Joint Surg Am. 2013; 95(24):2215-21.
- Tao W, Shihao Z, Jiyuan D. Status quo and argument of mesenchymal stem cell therapy for osteoarthritis[J]. Academic J Pla Postgraduate Med School. 2017; (06):559-61.
- Mont M, Cherian J, Sierra R, et al. Nontraumatic osteonecrosis of the femoral head: where do we stand today? A ten-year update. J Bone Joint Surg Am 2015; 97:1604-27.
- Fellows C R, Matta C, Zakany R, et al. Adipose, bone marrow and synovial joint-derived mesenchymal stem cells for cartilage repair. Front Genet. 2016; 7:213.
- Yuan H, Zhang J, Guo C, et al. Clinical outcomes of osteonecrosis of the femoral head after autologous bone marrow stem cell implantation: a meta-analysis of seven case-control studies. Clinics. 2016; 70(2): 110-3.
- Andriolo L, Merli G, Tobar C, et al. Regenerative therapies increase survivorship of avascular necrosis of the femoral head: A systematic review and meta-analysis. Int Orthop. 2018; 42(7): 1689-704.
- Tabatabaee RM, Saberi S, Parvizi J et al. Combining concentrated autologous bone marrow stem cells injection with core decompression improves outcome for patients with early-stage osteonecrosis of the femoral head: A comparative study. J Arthroplasty. 2015; 30:11-15.
- Egger AC, Ballock RT. Osteonecrosis of the femoral head in an adolescent on long-term inhalational corticosteroids. Case Rep Pediatr. 2017; 2017;6969787.
- Lamb JN, Holton C, O'Connor P, Giannoudis PV. Avascular necrosis of the hip. Br Med J. 2019; 365:4.
- Shah K, Racine J, Jones L, et al. Pathophysiology and risk factors for osteonecrosis. Curr Rev Musculoskelet Med. 2015; 8:201-9.
- Choi H, Steinberg M, Cheng E. Osteonecrosis of the femoral head: diagnosis and classification systems. Curr Rev Musculoskelet Med. 2015; 8:210-20.
- READ THE FULL ARTICLE
For any technique error please contact us
American Journal of BioMedicine Volume 10, Issue 1, pages 25-34
Received December 31, 2021; revised February 28, 2022; accepted March 19, 2022; published March 20, 2022.
How to cite this article
Zingoni GMZ, Castillo PD, Aliperti CP, Horst DJ. Role of bone marrow-derived mesenchymal stem cells in treatment avascular necrosis of femoral head. American Journal of BioMedicine 2022;10(1):25-34.
3. Methods and patients